February 26, 2014
This article was reported by Fox Business.
Fox Business reported that the U.S. Food and Drug Administration (FDA) awarded "breakthrough therapy designation" to Bristol-Myers Squibb's investigational treatment for hepatitis C virus (HCV) infection on February 24. This rare designation expedites the development and review process of drugs for serious or life-threatening conditions as FDA puts them on a fast-track approval process and gives the drug manufacturers intensive guidance. The approval for Bristol-Myers' combination therapy of chronic HCV infection comes after preliminary data from an ongoing late-stage trial in which the drug manufacturer is evaluating an all-oral regimen of daclatasvir and asunaprevir without ribavirin.
No comments have been made.
|Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds|
|Which HIV Treatment Regimens Are Recommended for Newly Diagnosed Patients?|
|Weekly PRO 140 Antibody Injections May Work as HIV Maintenance Therapy|
|This Week in HIV Research: Effects of Treatment on Arterial Inflammation; Mortality Rate After 5 Years of Treatment Not Impacted by Initial CD4 Count|
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|